{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:45:53Z","timestamp":1792615553363,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"The Breast Cancer Research Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xcrm.2026.103099","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:05:10Z","timestamp":1792508710000},"page":"103099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The next click in antibody drug conjugate development"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8170-6720","authenticated-orcid":false,"given":"Avantika","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarat","family":"Chandarlapaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103099_bib1","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.103099_bib2","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103099_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","article-title":"Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding","volume":"16","author":"Chen","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.103099_bib4","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1038\/s41467-018-07608-w","article-title":"Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy","volume":"9","author":"Pereira","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103099_bib5","article-title":"EGFR-directed antibodies promote HER2 ADC internalization and efficacy","volume":"5","author":"Gupta","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.103099_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study","volume":"35","author":"Perez","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103099_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","article-title":"A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy","volume":"29","author":"Li","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.103099_bib8","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1038\/s41591-025-03792-7","article-title":"A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103099_bib9","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-20-0014","article-title":"First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer","volume":"20","author":"Pegram","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.103099_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41586-026-10789-w","article-title":"Modular in vivo antibody-ADC click to reverse drug resistance in tumours","volume":"657","author":"Simo","year":"2026","journal-title":"Nature"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:02:31Z","timestamp":1792612951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126005161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666379126005161"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103099","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The next click in antibody drug conjugate development","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103099"}}